✦ LIBER ✦

A phase 1b, open-label study of trebananib in combination with paclitaxel and carboplatin in patients with ovarian cancer receiving interval or primary debulking surgery

✍ Scribed by Vergote, I.; Oaknin, A.; Baurain, J.-F.; Ananda, S.; Wong, S.; Su, X.; Wu, B.; Zhong, Z.; Warner, D.; Casado, A.

Book ID: 126876678
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 453 KB
Volume: 50
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2014.06.010

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 1A/B study of combination carbopla

Phase 1A/B study of combination carboplatin, paclitaxel and ridaforolim- us in patients with solid, endometrial, and ovarian cancers

✍ Chon, H.; Herschberger, A.; Lee, J.; Wenham, R. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 252 KB

9165 Motesanib or bevacizumab in combina

9165 Motesanib or bevacizumab in combination with paclitaxel and carboplatin in patients with advanced nonsquamous non-small cell lung cancer (NSCLC): interim results from a randomized, open-label, phase 2 study

✍ Blumenschein, G.; Schwartzberg, L.S.; Menon, H.; Mok, T.S.K.; Stephenson, J.J.; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

A phase II trial of a paclitaxel and oxa

A phase II trial of a paclitaxel and oxaliplatin combination in advanced ovarian cancer patients pretreated with cisplatin or carboplatin ± taxanes: Preliminary results

✍ Viens, P.; Bougnoux, P.; Rixe, O.; Petit, T.; Laadem, A.; Cottu, P.; Delva, R.; 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 186 KB

A phase 1 and pharmacodynamic study of d

A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer

✍ Fang Fang; Curt Balch; Jeanne Schilder; Timothy Breen; Shu Zhang; Changyu Shen; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 412 KB 👁 2 views

## Abstract ## BACKGROUND: Aberrant DNA methylation is a hallmark of cancer, and DNA methyltransferase inhibitors have demonstrated clinical efficacy in hematologic malignancies. On the basis of preclinical studies indicating that hypomethylating agents can reverse platinum resistance in ovarian c

Phase I feasibility trial of carboplatin

Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study

✍ Katherine Y Look; Michael A Bookman; Jessie Schol; Thomas J Herzog; Thomas Rocer 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 128 KB

A phase I study of intraperitoneal carbo

A phase I study of intraperitoneal carboplatin with intravenous paclitaxel and bevacizumab in patients with previously untreated epithelial ovarian carcinoma or primary peritoneal carcinoma

✍ O’Malley, D.; Eisenhauer, E.; McCann, G.; Salani, R.; Backes, F.; Copeland, L.; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 55 KB